NCT06909799View on ClinicalTrials.gov

A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease

NARecruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Tuberculosis (TB)
Interventions
DRUG

N-Acetyl Cysteine (NAC)

NAC will be provided as 600 mg capsules from NOW Healthgroup. Standard TB treatment will be provided as fixed dose combination tablets.

DRUG

Standard TB treatment

Standard TB treatment will be provided as fixed dose combination tablets.

Trial Locations (1)

Unknown

RECRUITING

MRC Unit The Gambia at LSHTM, Fajara

All Listed Sponsors
collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

Research Center Borstel

OTHER

lead

The Aurum Institute NPC

OTHER